A comparative QSAR analysis and molecular docking studies of quinazoline derivatives as tyrosine kinase (EGFR) inhibitors: A rational approach to anticancer drug design

Journal of Saudi Chemical Society

Volumn 17, Issue 4, 2013, Pages 361-379

  Noolvi, Malleshappa N ^a   Patel, Harun M ^a  

^a ASBASJSM College of Pharmacy   (India)

Author keywords

KNN MFA; Molecular docking; Multiple linear regression (MLR); Partial least squares (PLS); Principal component regression (PCR); Protein tyrosine kinase (EGFR)

Indexed keywords

EID: 84884818663     PISSN: 13196103     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jscs.2011.04.017     Document Type: Article

References (39)

1. Abraham D.J., Kellogg G.E., Kubinyi H. 3D QSAR in Drug Design: Theory, Methods and Applications 1993, ESCOM, Leiden.
2. Badiger A.M., Noolvi M.N., Nayak P.V. QSAR study of benzthiazole derivatives as p56 lck inhibitors. Lett. Drug Des. Discov. 2006, 3:550-560.
3. Ballard P., Bradbury R.H., Hennequin L.F.A., Hickinson D.M., Johnson P.D., Kettle J.G., Klinowska T., Morgentin R., Ogilvie D.J., Olivier A. 5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase. Bioorg. Med. Chem. Lett. 2005, 15:4226-4229.
4. Bridges A.J., Zhou H., Cody D.R., Rewcastle G.W., McMichael A., Showalter H.D.H., Fry D.W., Kraker A.J., Denny W.A. Tyrosine kinase inhibitors. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J. Med. Chem. 1996, 39:267-276.
5. Cramer R.D., Patterson D.E., Bunce J.D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110:5959-5967.
6. Denny W.A. The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases. IL Farmaco 2001, 56:51-56.
7. Fry D.W., Kraker A.J., McMichael A., Ambroso L.A., Nelson J.M., Leopold W.R., Connors R.W., Bridges A.J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994, 265:1093.
8. Gehlhar D.K., Verkhivker G.M., Rejto P.A., Sherman C.J., Fogel D.B., Fogel L.J., Freer S.T. Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming. Chem. Biol. 1995, 2:317-324.
9. Gibson K.H., Grundy W., Godfrey A.A., Woodburn J.R., Ashton S.E., Curry B.J., Scarlett L., Barker A.J., Brown D.S. Epidermal growth factor receptor tyrosine kinase: structure-activity relationships and antitumour activity of novel quinazolines. Bioorg. Med. Chem. Lett. 1997, 7:2723-2728.
10. Gilbert N. Statistics 1976, W.B. Saunders Co., Philadelphia PA.
11. Golbraikh A., Tropsha A. Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection. J. Comput. Aided Mol. Des. 2002, 16:357-369.
12. Golbraikh A., Tropsha A. QSAR modeling using chirality descriptors derived from molecular topology. J. Chem. Inf. Comput. Sci. 2003, 43:144-154.
13. Halgren T.A. Merck molecular force field. III. Molecular geometries and vibrational frequencies. J. Comput. Chem. 1996, 17:553-586.
14. Hennequin L.F.A., Ballard P., Boyle F.T., Delouvrie B., Ellston R.P.A., Halsall C.T., Harris C.S., Hudson K., Kendrew J., Pease J.E., Ross H.S., Smith P. Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. 2006, 16:2672-2676.
15. Herbst R.S., Fukuoka M., Baselga J. Gefitinib - a novel targeted approach to treating cancer. Nat. Rev. Cancer 2004, 4:956-965.
16. Holland J. Adaptation in Natural and Artificial Systems 1975, University of Michigan Press.
17. Hoskuldsson A. A combined theory for PCA and PLS. J. Chemometr. 1995, 9:91-123.
18. Manjula S.N., Noolvi M.N., Parihar K.V., Manohara Reddy S.A., Ramani V., Gadad A.K., Singh G., Kutty N.G., Rao M. Synthesis and anti-tumour activity of optically active thiourea and their 2-aminobenzothiazole derivatives: a novel class of anticancer agents. Eur. J. Med. Chem. 2009, 44:2923-2929.
19. Molecular Design Suite 3.5, VLife Technologies, Pune, India. http://www.vlifesciences.com.
20. Nandi S., Bagchi M.C. QSAR of amino pyrido[2,3-d]pyrimidin-7-yl derivatives: anticancer drug design by computed descriptors. J. Enzyme Inhib. Med. Chem. 2009, 24:937-948.
21. Noolvi M.N., Patel H.M. Synthesis and in vitro antitumor activity of substituted quinazoline and quinoxaline derivatives: search for anticancer agent. Eur. J. Med. Chem. 2011, 46:2327-2346.
22. Noolvi M.N., Patel H.M. 2D QSAR studies on a series of quinazoline derivatives as tyrosine kinase (EGFR) inhibitor: an approach to design anticancer agents. Lett. Drug Des. Discov. 2011, 7:556-586.
23. Noolvi, M.N., Patel, H.M. 2011c. Synthesis, method optimization, anticancer activity of 2,3,7-trisubstituted quinazoline derivatives and targeting EGFR-tyrosine kinase by rational approach. Arab. J. Chem., in press.
24. Noolvi M.N., Patel H.M., Bhardwaj B. 2D QSAR studies on a series of 4-anilino quinazoline derivatives as tyrosine kinase (EGFR) inhibitor: an approach to design anti cancer agents. Digest J. Nanomater. Biostruct. 2010, 5:387-401.
25. Noolvi, M.N., Patel, H.M., Agrawal, S., Zambre, A., Badiger, A. 2011a. Synthesis, antimicrobial and cytotoxic activity of novel 4 azetidine-2-one derivatives of 1H-benzimidazole. Arab. J. Chem., in press.
26. Noolvi, M.N., Patel, H.M., Bhardwaj, B. 2011b. An approach to design anticancer agents by 2D QSAR studies on a series of quinazoline analogues as tyrosine kinase (erbB-2) inhibitors. Med. Chem. 7, in press.
27. Oprea T.I., Waller C.L., Marshall G.R. Three-dimensional quantitative structure-activity relationship of human immunodeficiency virus (I) protease inhibitors. 2. Predictive power using limited exploration of alternate binding modes. J. Med. Chem. 1994, 37:2206.
28. Rewcastle G.W., Denny W.A., Bridges A.J., Zhou H., Cody D.R., McMichael A., Fry D.W. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl) amino]- and 4-(phenylamino) quinazolines as potent adeonosine-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J. Med. Chem. 1995, 38:3482-3487.
29. Sharaf M.A., Illman D.L., Kowalski B.R. Chemometrics 1986, Wiley, New York.
30. Shen M., LeTiran A., Xiao Y., Golbraikh A., Kohn H., Tropsha A. Quantitative structure-activity relationship analysis of functionalized amino acid anticonvulsant agents using k nearest neighbor and simulated annealing PLS methods. J. Med. Chem. 2002, 45:2811-2823.
31. Stamos J., Sliwkowski M.X., Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 2002, 277:46265-46272.
32. Sun L., Xie Y., Song X., Wang J., Yu R. Cluster analysis by simulated annealing. Comput. Chem. 1994, 18:103-108.
33. Verkhivker G.M., Bouzida D., Gehlhaar D.K., Rejto P.A., Arthurs S., Colson A.B., Freer S.T., Larson V., Luty B.A., Marrone T., Rose P.W. Deciphering common failures in molecular docking of ligand-protein complexes. J. Comput. Aided Mol. Des. 2000, 14:731-751.
34. VLife MDS 3.0 Documentation. 2007a. Tutorial: Engine Build Molecule, pp. 1-12.
35. VLife MDS 3.0 Documentation. 2007b. Tutorial: Protein Complex Optimization, pp. 1-8.
36. VLife MDS 3.0 Documentation. 2007c. Tutorial: Engine Build Molecule, pp. 17-20.
37. VLife MDS 3.0 Documentation. 2007d. Tutorial: Engine Build Molecule, pp. 9-14.
38. VLife MDS 3.0 Documentation. 2007e. Tutorial: Biopredicta Protein Complex Optimization, pp. 2-11.
39. Zheng W., Tropsham A. Novel variable selection quantitative structure-property relationship approach based on the k-nearest-neighbor principle. J. Chem. Inf. Comput. Sci. 2000, 40:185-194.